Reuters logo
BRIEF-Fibrocell reports interim results of phase 1/2 clinical trial of fcx-007 gene therapy
September 26, 2017 / 12:33 PM / a month ago

BRIEF-Fibrocell reports interim results of phase 1/2 clinical trial of fcx-007 gene therapy

Sept 26 (Reuters) - Fibrocell Science Inc:

* Fibrocell reports interim results of phase 1/2 clinical trial of fcx-007 gene therapy for recessive dystrophic epidermolysis bullosa

* Fibrocell Science Inc says data from patients show fcx-007 was well-tolerated through 12 weeks post-administration

* Fibrocell science inc says compared to baseline measurement collected, at four weeks post-administration 100 pct (5/5) of wounds were > 75 pct healed

* Fibrocell Science Inc - ‍with data from first 3 patients meeting primary trial objective of safety, co plans to increase expression and dosing fcx-007​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below